Management Team
| Michael S. Anderson |
Chief Executive Officer
Michael S. Anderson was appointed Chief Executive Officer of Flamel Technologies in March 2012. Previously, Anderson was the President and Chief Executive Officer of Éclat Pharmaceuticals, a specialty pharma company located in St. Louis, Missouri. Éclat, which began operation in November 2010, was acquired by Flamel in March of this year. Prior to Eclat, Anderson was at KV Pharmaceutical Company, where he served as President and CEO of its generic business, ETHEX Corporation, and was also the President and CEO of Ther-Rx Corporation, a leader in women’s healthcare. He also was with Schein Pharmaceutical and started his career with A.H. Robins Company. He will be relocating to Lyon, France and Éclat will continue to be operated out of St. Louis.
|
|---|---|
| Rafael Jorda, Ph.D. |
Executive Vice President, Chief Operating Officer
Dr. Rafael Jorda has been Executive Vice President and Chief Operating Officer of Flamel Technologies SA since 2005. He joined the Company in early 1991. Previously Mr. Jorda worked 14 years as a research and development scientist on controlled-released and biopolymers at Rhone-Poulenc. He is specialized in chemical engineering and in the structure-property relationships of materials. Mr Jorda is a graduate of “Ecole Nationale Supérieure de Chimie de Lyon” (France).
|
| Siân Crouzet |
Principal Financial Officer
Mrs. Sian Crouzet has been Principal Financial Officer of Flamel Technologies SA since March 2008. She previously worked as Financial Controller France for McCormick & Company Inc. Mrs. Crouzet also worked five years as an external auditor with Ernst and Young (France and UK). She is a UK Chartered Accountant and a graduate of Bradford University (UK).
|
| Yves Bourboulou, Pharm.D. |
Director, Manufacturing Facility
Mr. Yves Bourboulou is Director of Manufacturing Facility. He worked previously as Plant Manager at Pharmacia and Fresenius Kabi. Mr. Bourboulou previously held various senior positions including Quality Assurance Director and Chief Pharmacist Officer (CPO) in the Pharmaceutical Industry. He has more than 20 years experience in pharmaceutical production, quality and development.
|
| Nigel McWilliam |
Vice President, Business Development
Mr. Nigel McWilliam is Vice President of Business Development. He joined the Company in its Washington office in August 2005. Mr. McWilliam spent 20 years with Dow Corning Corporation’s Health Care Businesses in commercial positions in Europe and the U.S. He also had various senior positions as President of Leiras Inc., the U.S. subsidiary of a Finnish pharmaceutical company (now part of Bayer-Schering, AG), as CEO of Veos Ltd., and as Senior V.P. Business Development at SkyePharma. Mr. McWilliam has a Bachelor degree in Science from the University of Dundee.
|
| Jean Chatellier, Ph.D. |
Vice President, Alliance Management
Dr. Jean Chatellier is Vice President of Alliance Management. He joined Flamel Technologies in October 2010. He served previously as Director of Business Development at Micromet AG (Nasdaq: MITI) and added other business development activities for Crucell (Nasdaq: CRXL) and Viropro Inc. (PINK: VPRO). He also was the founder and CEO of Imaxio SA, and was ex-CEO and liquidator of Aptanomics SA. He obtained a binational Ph.D. in Protein Engineering from Strasbourg, France and Montréal, Canada. He also performed post-doctoral research with Sir Allan Fersht and Sir Greg Winter at the Center for Protein Engineering of the Medical Research Council, Cambridge UK.
|
| Christian Kalita, Pharm.D. |
Chief Pharmaceutical Officer, Director of Quality and Regulatory Affairs
Mr. Christian Kalita has been Chief Pharmaceutical Officer, Director of Quality and Regulatory Affairs of Flamel Technologies SA since 2005. He worked previously at SkyePharma as Director of Quality for Europe. Mr. Kalita also worked 10 years for Merck Lipha and Merck generics in different roles as Chief Pharmaceutical Officer, Head of Quality Control Management and Head of Industrial Affairs.
|
| Rémi Meyrueix, Ph.D. |
Director, Medusa Platform (Injectable Drugs)
Dr. Rémi Meyrueix is Director of Medusa Platform of Flamel Technologies SA. He joined the Company in early 1991 after having spent 8 years at Rhone Poulenc. Mr. Meyrueix holds an engineer degree and a Ph.D. in physics from the Polytechnic Institute of Grenoble (France).
|
| Catherine Castan, Ph.D. |
Director, Micropump Platform (Oral Drugs) and Intellectual Property
Dr. Catherine Castan is Director of Micropump Platform (Oral Drugs) and Intellectual Property of Flamel Technologies SA. She joined the Company in 1992 after having spent 4 years at Sanofi Recherche. Mrs. Castan is a graduate of “Ecole Nationale Supérieure de Chimie de Montpellier” and has a Ph.D. in polymer chemistry, applied in drug delivery.
|
| You-Ping Chan, Ph.D. |
Director, Chemistry and Analysis
Dr. You-Ping Chan is Director of Chemistry and Analysis of Flamel Technologies SA. He joined the Company in 1992 as a researcher in polymer science after post-doctoral research at the Massachusetts Institute of Technology (USA). He received his Ph.D. in Chemistry from Strasbourg, France.
|
| Roger Kravtzoff, Ph.D. |
Director, Preclinical and Clinical Development
Dr. Roger Kravtzoff is Director of Preclinical and Clinical Development of Flamel Technologies SA. He joined the Company in June 2002. Previously, Mr. Kravtzoff worked as Project Director at Biovector Therapeutics. He also had senior scientist positions at Novacell and the “Centre Regional de Transfusion Sanguine”. Mr. Kravtzoff obtained a Ph.D. in Biochemistry from Tours, France.
|
Board of Directors
| Elie Vannier | Chairman (former Group Managing Director of WALLY and former Chief Operating Officer of GrandVision SA, Director of Ingénico, Famar, Conbipel and Deputy Chairman of the Supervisory Board Groupe Loret) |
|---|---|
| Francis J.T. Fildes, Ph.D. | Director (former Senior Vice President: Head of Global Development for AstraZeneca, PLC, Director of ProStrakan Group PLC and Fildes Partners Ltd, and a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry) |
| Lodewijk J.R. de Vink | Director (former President of Schering Plough International, former Chairman and Chief Executive Officer of Warner Lambert, Inc., Director of Alcon, Roche, and member of the International Advisory Board of Sotheby’s and Member of the European Advisory Council of Rothschild) |
| John L. Vogelstein | Director (former President of Warburg Pincus, Senior Advisor of Warburg Pincus, Chairman of New Providence Asset Management; Chairman of the New York City Ballet, Chairman of Prep for Prep,Vice Chairman of the Overseers Board of The Leonard N. Stern School of Business at New York University, Chairman of Third Way, Director of the Jewish Museum) |
| Catherine Bréchignac, Ph.D. | Director (Permanent Secretary of the French Academy of Sciences and former Chairwoman of the French National Center for Scientific Research, CNRS) |
| Guillaume Cerutti | Director (Chairman and CEO of Sotheby’s France) |
| the Honorable Craig Stapleton | Director (former United States Ambassador to France) |
| Stephen H. Willard | Director (former Chief Executive Officer, Chief Financial Officer and General Counsel of Flamel Technologies, Vice President of Biovail Corporation, Associate Director of Resolutions of the Federal Deposit Insurance Corporation (“FDIC”) of the USA, investment banker at Credit Suisse First Boston, and attorney with Gibson, Dunn & Crutcher LLP and Shearman & Sterling LLP; member of the Board of Directors of E-Trade Financial Corporation) |
Scientific Advisory Board
| Professor Jean-Marie Lehn | 1987 Nobel Laureate in Chemistry, Professor at Collège de France, former member of the French Government’s « Haut Conseil de la Science et de la Technologie ». |
|---|---|
| Professor Christian Trepo | Professor of hepato-gastroenterology at the A. Carrel Faculty of Medicine, former Head of the Internal Medicine Department and Head of the Hepato-Gastroenterology Department (Hôtel Dieu, Hospices Civils de Lyon). |
